Photocure ASA (PHO.OL) Stock Analysis & Winston Score

Photocure ASA is a Norwegian biotech company that makes a medical drug used to detect bladder cancer. Its main product is Cysview (called Hexvix in Europe), a liquid solution that doctors put into the bladder before a procedure called cystoscopy. When exposed to blue light, cancer cells glow pink, making them much easier to spot than with standard white-light cameras alone. The company earns money by selling Cysview to hospitals and urology clinics, primarily in the United States and across Europe. With a gross margin above 90%, the business is highly efficient once the drug is sold — the main cost is sales and marketing, not manufacturing. Photocure's competitive position rests on its patented technology and the fact that Cysview is the only FDA-approved optical imaging agent for bladder cancer detection in the U.S. The key growth driver is expanding the number of hospitals that adopt blue-light cystoscopy, though the slow pace of clinical adoption remains the central risk to revenue growth.